Quoin Pharmaceuticals (QNRX) News
NASDAQ: QNRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.28-0.0791 (-2.35%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
QNRX news summary
We found 7 recent headlines mentioning Quoin Pharmaceuticals (QNRX): 0 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, QNRX is down 2.35% at $3.28. The most recent story, "Quoin Pharmaceuticals, Ltd. Reports Third Quarter 2026 Financial Results", was published by Nasdaq on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Quoin Pharmaceuticals headlines
- Quoin Pharmaceuticals, Ltd. Reports Third Quarter 2026 Financial ResultsQuoin Pharmaceuticals, Ltd. reported its financial results for the third quarter ended September 30, 2026. The company had approximately $33.2 million in cash, cash equivalents, and marketable…Nasdaq
- Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton SyndromeQuoin (NASDAQ: QNRX) released a new NETHERTON NOW episode featuring Kristi and Kodi, a family living with Netherton Syndrome, and Dr. Moise Levy.GlobeNewswire
- Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsQuoin reports Q3 2026 results, positive interim Phase 2/3 QRX003 data in Netherton Syndrome, up to $50M private placement and new PSS designations.GlobeNewswire
- Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026GlobeNewswire
- Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and TherapyQuoin Pharmaceuticals publishes peer-reviewed QRX003 case report detailing 21 months of pediatric compassionate-use treatment for Netherton Syndrome.GlobeNewswire
- Quoin Secures EMA Orphan Drug Designation For QRX003 In Rare Skin Disorder(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX) has received Orphan Drug Designation from the European Medicines Agency for QRX003 as a potential treatment for Peeling Skin Syndrome, a rare inherited…NasdaqQNRX, ET
- Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin SyndromeEMA grants Orphan Drug Designation to investigational QRX003 for Peeling Skin Syndrome, its eighth regulatory designation across two indications.GlobeNewswire